Jan Øystein Berle

Summary

Affiliation: University of Bergen
Country: Norway

Publications

  1. ncbi Breastfeeding during maternal antidepressant treatment with serotonin reuptake inhibitors: infant exposure, clinical symptoms, and cytochrome p450 genotypes
    Jan Øystein Berle
    Centre for Child and Adolescent Mental Health, University of Bergen, Bergen, Norway
    J Clin Psychiatry 65:1228-34. 2004
  2. ncbi [Psychiatric disorders during pregnancy and lactation]
    Jan Øystein Berle
    Regionsenter for barne og ungdomspsykiatri, Helseregion Vest, Postboks 7800, 5020 Bergen
    Tidsskr Nor Laegeforen 123:2037-40. 2003
  3. ncbi [Are mood stabilizers beneficial in the treatment of schizophrenia?]
    Jan Øystein Berle
    Fjell og Arstad DPS Avdeling Knappentunet, Helse Bergen HF, Haukeland Universitetssjukehus, 5021 Bergen og Regionsenter for barn og unges psykiske helse, Helseregion Vest Bergen
    Tidsskr Nor Laegeforen 125:1809-12. 2005

Detail Information

Publications3

  1. ncbi Breastfeeding during maternal antidepressant treatment with serotonin reuptake inhibitors: infant exposure, clinical symptoms, and cytochrome p450 genotypes
    Jan Øystein Berle
    Centre for Child and Adolescent Mental Health, University of Bergen, Bergen, Norway
    J Clin Psychiatry 65:1228-34. 2004
    ....
  2. ncbi [Psychiatric disorders during pregnancy and lactation]
    Jan Øystein Berle
    Regionsenter for barne og ungdomspsykiatri, Helseregion Vest, Postboks 7800, 5020 Bergen
    Tidsskr Nor Laegeforen 123:2037-40. 2003
    ..The use of drugs is a particularly difficult issue, as detrimental effects may arise in the fetus and in the suckling infant...
  3. ncbi [Are mood stabilizers beneficial in the treatment of schizophrenia?]
    Jan Øystein Berle
    Fjell og Arstad DPS Avdeling Knappentunet, Helse Bergen HF, Haukeland Universitetssjukehus, 5021 Bergen og Regionsenter for barn og unges psykiske helse, Helseregion Vest Bergen
    Tidsskr Nor Laegeforen 125:1809-12. 2005
    ..Antipsychotic agents are the drugs of choice in the treatment of schizophrenia. However, some patients profit only modestly from such therapy and thus represent a clinical challenge...